首页 > 最新文献

Acta Psychiatrica Scandinavica最新文献

英文 中文
The impact of sex in the effectiveness of functional remediation in bipolar disorder 性别对双相情感障碍功能性矫正效果的影响。
IF 5.3 2区 医学 Q1 PSYCHIATRY Pub Date : 2024-09-07 DOI: 10.1111/acps.13748
Maria Serra-Navarro, Derek Clougher, Brisa Solé, Jose Sánchez-Moreno, Ana González-Pinto, Esther Jiménez, Benedikt L. Amann, Vicent Balanzá-Martínez, Rafael Tabarés-Seisdedos, Celso Arango, Vivian Accardo, María Paz García-Portilla, Ángela Ibáñez, José Manuel Crespo, José Luis Ayuso-Mateos, Silvia Amoretti, Carla Torrent, Anabel Martínez-Aran, Eduard Vieta, CIBERSAM Functional Remediation Group

Background

Functional recovery remains a core clinical objective for patients with bipolar disorder (BD). Sociodemographic, clinical, and neurocognitive variables are associated with long-term functional impairment, yet the impact of sex differences is unclear. Functional remediation (FR) is a validated intervention aimed at achieving functional recovery in BD. The present study assessed the effect of sex differences of FR on psychosocial functioning at post-treatment (6-months) and 12-month follow-up (FUP). To the best of our knowledge, this is the first study to explore the role of sex as a factor in the efficacy of FR.

Methods

157 participants with BD were randomly assigned to either FR (N = 77) or treatment as usual group (80). Clinical, sociodemographic, neuropsychological, and functional data were obtained using a comprehensive assessment battery. Sex differences were explored via a general linear model (GLM) for repeated measures to compare the effect of sex on the intervention over time (6 months and FUP).

Results

Results demonstrated that FR benefits both sexes, males (p = 0.001; d’ = 0.88) and females (p = 0.04; d’ = 0.57), at 6 months suggesting a generalized functional improvement. Conversely, at 12-month FUP sex differences were observed only in males (p = 0.005; d’ = 0.68).

Conclusions

FR is a beneficial intervention for males and females after treatment, suggesting that there are no relevant distinct needs. Females may benefit from ongoing psychosocial functioning booster sessions after the intervention to maintain original improvements. Future research exploring sex differences could help to identify strategies to offer personalized FR intervention approaches in individuals with BD.

背景:功能恢复仍是双相情感障碍(BD)患者的核心临床目标。社会人口学、临床和神经认知变量与长期功能障碍有关,但性别差异的影响尚不明确。功能性补救(FR)是一种有效的干预措施,旨在实现双相情感障碍患者的功能恢复。本研究评估了性别差异对治疗后(6 个月)和 12 个月随访(FUP)期间心理社会功能的影响。方法:157 名 BD 患者被随机分配到 FR 组(77 人)或常规治疗组(80 人)。使用综合评估电池获取临床、社会人口学、神经心理学和功能数据。通过重复测量的一般线性模型(GLM)探讨了性别差异,以比较性别在不同时间(6 个月和家庭综合评估)对干预的影响:结果表明,在 6 个月时,FR 对男性(p = 0.001;d' = 0.88)和女性(p = 0.04;d' = 0.57)都有益处,表明功能得到了普遍改善。相反,在为期 12 个月的功能障碍评估中,仅在男性中观察到性别差异(p = 0.005;d' = 0.68):结论:FR 在治疗后对男性和女性都是一种有益的干预措施,这表明并不存在相关的不同需求。女性可能会受益于干预后持续的社会心理功能强化训练,以保持原有的改善。未来探索性别差异的研究将有助于确定为 BD 患者提供个性化 FR 干预方法的策略。
{"title":"The impact of sex in the effectiveness of functional remediation in bipolar disorder","authors":"Maria Serra-Navarro,&nbsp;Derek Clougher,&nbsp;Brisa Solé,&nbsp;Jose Sánchez-Moreno,&nbsp;Ana González-Pinto,&nbsp;Esther Jiménez,&nbsp;Benedikt L. Amann,&nbsp;Vicent Balanzá-Martínez,&nbsp;Rafael Tabarés-Seisdedos,&nbsp;Celso Arango,&nbsp;Vivian Accardo,&nbsp;María Paz García-Portilla,&nbsp;Ángela Ibáñez,&nbsp;José Manuel Crespo,&nbsp;José Luis Ayuso-Mateos,&nbsp;Silvia Amoretti,&nbsp;Carla Torrent,&nbsp;Anabel Martínez-Aran,&nbsp;Eduard Vieta,&nbsp;CIBERSAM Functional Remediation Group","doi":"10.1111/acps.13748","DOIUrl":"10.1111/acps.13748","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Functional recovery remains a core clinical objective for patients with bipolar disorder (BD). Sociodemographic, clinical, and neurocognitive variables are associated with long-term functional impairment, yet the impact of sex differences is unclear. Functional remediation (FR) is a validated intervention aimed at achieving functional recovery in BD. The present study assessed the effect of sex differences of FR on psychosocial functioning at post-treatment (6-months) and 12-month follow-up (FUP). To the best of our knowledge, this is the first study to explore the role of sex as a factor in the efficacy of FR.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>157 participants with BD were randomly assigned to either FR (<i>N</i> = 77) or treatment as usual group (80). Clinical, sociodemographic, neuropsychological, and functional data were obtained using a comprehensive assessment battery. Sex differences were explored via a general linear model (GLM) for repeated measures to compare the effect of sex on the intervention over time (6 months and FUP).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Results demonstrated that FR benefits both sexes, males (<i>p</i> = 0.001; d’ = 0.88) and females (<i>p</i> = 0.04; d’ = 0.57), at 6 months suggesting a generalized functional improvement. Conversely, at 12-month FUP sex differences were observed only in males (<i>p</i> = 0.005; d’ = 0.68).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>FR is a beneficial intervention for males and females after treatment, suggesting that there are no relevant distinct needs. Females may benefit from ongoing psychosocial functioning booster sessions after the intervention to maintain original improvements. Future research exploring sex differences could help to identify strategies to offer personalized FR intervention approaches in individuals with BD.</p>\u0000 </section>\u0000 </div>","PeriodicalId":108,"journal":{"name":"Acta Psychiatrica Scandinavica","volume":"150 6","pages":"543-561"},"PeriodicalIF":5.3,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142144496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Childhood maltreatment and outcomes following electroconvulsive therapy in adults with depression 儿童时期的虐待与成年抑郁症患者接受电休克治疗后的结果。
IF 5.3 2区 医学 Q1 PSYCHIATRY Pub Date : 2024-09-05 DOI: 10.1111/acps.13756
Ana Jelovac, Christopher Mohan, Emma Whooley, Anna Igoe, Cathal McCaffrey, Declan M. McLoughlin

Objective

Childhood maltreatment is associated with less favourable treatment outcomes with pharmacotherapy and psychotherapy for depression. It is unknown whether this increased risk of treatment resistance in maltreated individuals extends to electroconvulsive therapy (ECT).

Methods

This retrospective cohort study included 501 consecutive adult referrals for an acute course of twice-weekly ECT for unipolar or bipolar depression at an academic inpatient centre in Ireland between 2016 and 2024. Retrospectively reported physical and sexual childhood maltreatment were assessed on hospital admission. Response was defined as a score of 1 or 2 and remission was defined as a score of 1 on the Clinical Global Impression – Improvement scale 1–3 days after final ECT session. Logistic regression analyses were used to examine the associations between childhood maltreatment and ECT nonresponse and nonremission, adjusting for covariates. Mediation analyses were conducted to explore the role of psychiatric comorbidities, persistent depressive symptoms lasting 2 years or more in the current episode, and baseline depression severity.

Results

Compared to the group with no childhood maltreatment, the childhood maltreatment group had similar odds of ECT nonresponse (adjusted odds ratio = 1.47, 95% CI = 0.85–2.53) but significantly elevated odds of ECT nonremission (adjusted odds ratio = 3.75, 95% CI = 1.80–7.81). In a mediation analysis, presence of persistent depressive symptoms mediated 7.4% of the total effect of childhood maltreatment on ECT nonremission.

Conclusion

Individuals with exposure to childhood maltreatment may be less likely to achieve full remission following a course of ECT.

目的:儿童时期的虐待与抑郁症药物治疗和心理治疗的不良疗效有关。目前尚不清楚受虐待者治疗抵抗风险的增加是否也会影响到电休克疗法(ECT):这项回顾性队列研究纳入了2016年至2024年期间爱尔兰一家学术住院中心连续转诊的501名成人患者,这些患者因单相或双相抑郁症接受了每周两次的急性ECT治疗。入院时对回顾性报告的童年身体虐待和性虐待进行了评估。最后一次电疗疗程后1-3天,临床总体印象--改善量表得分达到1分即为应答,得分达到2分即为缓解。逻辑回归分析用于研究童年虐待与 ECT 无应答和无缓解之间的关系,并对协变量进行了调整。研究人员还进行了中介分析,以探讨精神疾病合并症、持续2年或更长时间的抑郁症状和基线抑郁严重程度的作用:与无童年虐待组相比,童年虐待组的电疗无反应几率相似(调整后的几率比=1.47,95% CI=0.85-2.53),但电疗无缓解几率显著升高(调整后的几率比=3.75,95% CI=1.80-7.81)。在中介分析中,持续抑郁症状的存在中介了儿童虐待对电疗无效总影响的7.4%:结论:受过童年虐待的人在接受电痉挛疗法治疗后完全缓解的可能性较小。
{"title":"Childhood maltreatment and outcomes following electroconvulsive therapy in adults with depression","authors":"Ana Jelovac,&nbsp;Christopher Mohan,&nbsp;Emma Whooley,&nbsp;Anna Igoe,&nbsp;Cathal McCaffrey,&nbsp;Declan M. McLoughlin","doi":"10.1111/acps.13756","DOIUrl":"10.1111/acps.13756","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Childhood maltreatment is associated with less favourable treatment outcomes with pharmacotherapy and psychotherapy for depression. It is unknown whether this increased risk of treatment resistance in maltreated individuals extends to electroconvulsive therapy (ECT).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This retrospective cohort study included 501 consecutive adult referrals for an acute course of twice-weekly ECT for unipolar or bipolar depression at an academic inpatient centre in Ireland between 2016 and 2024. Retrospectively reported physical and sexual childhood maltreatment were assessed on hospital admission. Response was defined as a score of 1 or 2 and remission was defined as a score of 1 on the Clinical Global Impression – Improvement scale 1–3 days after final ECT session. Logistic regression analyses were used to examine the associations between childhood maltreatment and ECT nonresponse and nonremission, adjusting for covariates. Mediation analyses were conducted to explore the role of psychiatric comorbidities, persistent depressive symptoms lasting 2 years or more in the current episode, and baseline depression severity.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Compared to the group with no childhood maltreatment, the childhood maltreatment group had similar odds of ECT nonresponse (adjusted odds ratio = 1.47, 95% CI = 0.85–2.53) but significantly elevated odds of ECT nonremission (adjusted odds ratio = 3.75, 95% CI = 1.80–7.81). In a mediation analysis, presence of persistent depressive symptoms mediated 7.4% of the total effect of childhood maltreatment on ECT nonremission.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Individuals with exposure to childhood maltreatment may be less likely to achieve full remission following a course of ECT.</p>\u0000 </section>\u0000 </div>","PeriodicalId":108,"journal":{"name":"Acta Psychiatrica Scandinavica","volume":"151 1","pages":"46-55"},"PeriodicalIF":5.3,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/acps.13756","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142131270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between exposure to atypical antipsychotics during pregnancy and risk of miscarriage 孕期接触非典型抗精神病药物与流产风险之间的关系。
IF 5.3 2区 医学 Q1 PSYCHIATRY Pub Date : 2024-09-05 DOI: 10.1111/acps.13755
Tomofumi Ishikawa, Takamasa Sakai, Noriyuki Iwama, Ryo Obara, Kei Morishita, Motohiko Adomi, Aoi Noda, Mami Ishikuro, Saya Kikuchi, Natsuko Kobayashi, Hiroaki Tomita, Masatoshi Saito, Hidekazu Nishigori, Shinichi Kuriyama, Nariyasu Mano, Taku Obara

Objective

To evaluate the association between exposure to atypical antipsychotics during pregnancy and risk of miscarriage.

Material and Methods

This nested case–control study used a large Japanese administrative database. Pregnancy onset and outcomes were estimated using previously reported algorithms, classifying cases as women becoming pregnant between 2013 and 2022 and ending in a miscarriage. Controls were randomly selected from the entire pregnancy cohort by risk-set sampling with replacement and were individually matched to the cases (3:1). The association between exposure to atypical antipsychotics and risk of miscarriage was assessed using conditional logistic regression adjusted for confounders. The association between benzodiazepine exposure and the risk of miscarriage was assessed as a positive control.

Results

In the cohort, 44,118 patients were matched with 132,317 controls. The mean ages (standard deviations) of the case and control groups were 33.3 (5.7) and 33.2 (5.5) years, respectively. The prevalence of atypical antipsychotics was 0.5% in both groups. Aripiprazole is an individual antipsychotic with the highest prescription prevalence. The adjusted odds ratios (aOR) for miscarriage were 0.966 (95% confidence interval [CI], 0.796–1.173) for atypical antipsychotics and 0.998 (0.784–1.269) for aripiprazole. A higher aOR (1.431, 95% CI 1.303–1.573) suggested an association with benzodiazepines. A sensitivity analysis that limited the population to women diagnosed with schizophrenia alone did not suggest an association between atypical antipsychotics and the risk of miscarriage.

Conclusions

The results of this study do not suggest an association between exposure to atypical antipsychotics during pregnancy and the risk of miscarriage.

目的:评估孕期接触非典型抗精神病药物与流产风险之间的关系:评估孕期接触非典型抗精神病药物与流产风险之间的关系:这项巢式病例对照研究使用了日本的大型行政数据库。妊娠起始时间和妊娠结局采用之前报道过的算法进行估计,将病例归类为在 2013 年至 2022 年期间怀孕并最终流产的女性。对照组是通过风险设置抽样从整个怀孕队列中随机抽取的,并与病例进行单独配对(3:1)。非典型抗精神病药物暴露与流产风险之间的关系采用条件逻辑回归进行评估,并对混杂因素进行了调整。苯二氮卓类药物暴露与流产风险之间的关系作为阳性对照进行评估:在队列中,44 118 名患者与 132 317 名对照者进行了配对。病例组和对照组的平均年龄(标准差)分别为 33.3(5.7)岁和 33.2(5.5)岁。两组中使用非典型抗精神病药物的比例均为 0.5%。阿立哌唑是处方率最高的一种抗精神病药物。非典型抗精神病药物的调整后流产几率(aOR)为0.966(95%置信区间[CI],0.796-1.173),阿立哌唑的调整后流产几率(aOR)为0.998(0.784-1.269)。较高的 aOR(1.431,95% CI 1.303-1.573)表明与苯二氮卓类药物有关。一项敏感性分析将研究对象限定为仅诊断出患有精神分裂症的女性,但该分析并未显示非典型抗精神病药物与流产风险之间存在关联:本研究的结果并不表明孕期接触非典型抗精神病药物与流产风险之间存在关联。
{"title":"Association between exposure to atypical antipsychotics during pregnancy and risk of miscarriage","authors":"Tomofumi Ishikawa,&nbsp;Takamasa Sakai,&nbsp;Noriyuki Iwama,&nbsp;Ryo Obara,&nbsp;Kei Morishita,&nbsp;Motohiko Adomi,&nbsp;Aoi Noda,&nbsp;Mami Ishikuro,&nbsp;Saya Kikuchi,&nbsp;Natsuko Kobayashi,&nbsp;Hiroaki Tomita,&nbsp;Masatoshi Saito,&nbsp;Hidekazu Nishigori,&nbsp;Shinichi Kuriyama,&nbsp;Nariyasu Mano,&nbsp;Taku Obara","doi":"10.1111/acps.13755","DOIUrl":"10.1111/acps.13755","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To evaluate the association between exposure to atypical antipsychotics during pregnancy and risk of miscarriage.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Material and Methods</h3>\u0000 \u0000 <p>This nested case–control study used a large Japanese administrative database. Pregnancy onset and outcomes were estimated using previously reported algorithms, classifying cases as women becoming pregnant between 2013 and 2022 and ending in a miscarriage. Controls were randomly selected from the entire pregnancy cohort by risk-set sampling with replacement and were individually matched to the cases (3:1). The association between exposure to atypical antipsychotics and risk of miscarriage was assessed using conditional logistic regression adjusted for confounders. The association between benzodiazepine exposure and the risk of miscarriage was assessed as a positive control.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In the cohort, 44,118 patients were matched with 132,317 controls. The mean ages (standard deviations) of the case and control groups were 33.3 (5.7) and 33.2 (5.5) years, respectively. The prevalence of atypical antipsychotics was 0.5% in both groups. Aripiprazole is an individual antipsychotic with the highest prescription prevalence. The adjusted odds ratios (aOR) for miscarriage were 0.966 (95% confidence interval [CI], 0.796–1.173) for atypical antipsychotics and 0.998 (0.784–1.269) for aripiprazole. A higher aOR (1.431, 95% CI 1.303–1.573) suggested an association with benzodiazepines. A sensitivity analysis that limited the population to women diagnosed with schizophrenia alone did not suggest an association between atypical antipsychotics and the risk of miscarriage.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The results of this study do not suggest an association between exposure to atypical antipsychotics during pregnancy and the risk of miscarriage.</p>\u0000 </section>\u0000 </div>","PeriodicalId":108,"journal":{"name":"Acta Psychiatrica Scandinavica","volume":"150 6","pages":"562-572"},"PeriodicalIF":5.3,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142131269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Monoamine oxidase inhibitors: Seriously underused in the treatment of major depression 单胺氧化酶抑制剂:治疗重度抑郁症的药物严重不足。
IF 5.3 2区 医学 Q1 PSYCHIATRY Pub Date : 2024-09-03 DOI: 10.1111/acps.13753
Tom K. Birkenhager, Willemijn T. Heijnen
<p>Monoamine oxidase inhibitors (MAOIs) were the first licensed antidepressants, they were discovered serendipitously, during a trial of iproniazid in patients with tuberculosis in the 1950s. Iproniazid appeared to have a “psychic energizing effect,” which resulted in the improvement of depressive symptoms in some tuberculosis patients,<span><sup>1</sup></span> around that time, iproniazid was shown to inhibit the MAO enzyme. Iproniazid was approved as an antidepressant, and this led to the development of several other MAOIs. Brain neurotransmitter levels are inactivated by MAO-A (serotonin, norepinephrine, dopamine) and MAO-B (dopamine) isoenzymes. Inhibition of the MAO enzyme leads to an increasing synaptic availability of these monoamines. In addition, tranylcypromine is similar in chemical structure to amphetamine and shares its dopamine-releasing and stimulant-like effects. Tranylcypromine and phenelzine are the most frequently used non-selective MAOIs, which bind the MAO enzyme irreversibly, and deactivate it permanently. Moclobemide is a selective MAO-A inhibitor, and enters into a reversible binding to the enzyme. Tranylcypromine and Phenelzine were widely prescribed until the late 1960s. The use of MAOIs has declined dramatically, as stated in their network meta-analysis by Gimenez-Palomo et al.<span><sup>2</sup></span> The historical perspective is important in understanding this decline.</p><p>In the 1960s it was not well understood that MAOIs inhibit the breakdown of tyramine, and that excessive tyramine intake when using an MAOI, can lead to a hypertensive crisis. A series of initially unexplained hypertensive crises actually occurred, some even resulting in stroke. The cause of this “cheese reaction” was uncovered in the late 1960s, but the fear for the hypertensive reaction remained. Furthermore, in one of the first large randomized clinical trials in psychiatry,<span><sup>3</sup></span> which included 260 depressed patients, both ECT and imipramine appeared to be effective, whereas phenelzine and placebo were not. In hindsight, one may well argue, that both the duration of treatment with phenelzine (4 weeks) and its dose (maximum 60 mg daily) were insufficient, therefore, phenelzine fell short of its full efficacy potential. Subsequently, MAOIs were regarded as not very effective and dangerous antidepressant drugs. This perception influenced physicians to strongly favor tricyclic antidepressants (TCAs) over MAOIs. Usage of MAOIs further declined, following the development of newer antidepressants, especially the selective serotonin reuptake inhibitors (SSRIs). Concerns about the safety profile of MAOIs, including potentially dangerous drug–drug interactions, which could result in serotonin syndrome, and the risk of a hypertensive crisis restricted their use. Furthermore, the use of MAOIs was not promoted by any pharmaceutical company.</p><p>In several countries the number of prescriptions of MAOIs is extremely low: about 500 patie
单胺氧化酶抑制剂(MAOIs)是第一种获得许可的抗抑郁药物,是在 20 世纪 50 年代对结核病患者进行异丙嗪试验时偶然发现的。异丙嗪似乎具有 "精神振奋作用",从而改善了一些肺结核患者的抑郁症状1。异丙嗪被批准为抗抑郁药,并由此带动了其他几种 MAOIs 的开发。大脑神经递质水平会被 MAO-A(血清素、去甲肾上腺素、多巴胺)和 MAO-B(多巴胺)同工酶灭活。抑制 MAO 酶会增加这些单胺类物质在突触中的供应量。此外,氨甲环酸的化学结构与苯丙胺相似,也具有释放多巴胺和类似兴奋剂的作用。曲酰丙咪嗪和苯乙肼是最常用的非选择性 MAOIs,它们与 MAO 酶的结合是不可逆的,并使其永久失活。吗氯贝胺是一种选择性 MAO-A 抑制剂,与 MAO 酶的结合是可逆的。曲安奈德和苯乙肼在 20 世纪 60 年代末之前一直被广泛使用。正如 Gimenez-Palomo 等人在其网络荟萃分析中所述,MAOIs 的使用已急剧下降。2 历史的视角对于理解这种下降非常重要。在 20 世纪 60 年代,人们还不太了解 MAOIs 可抑制酪胺的分解,以及在使用 MAOI 时摄入过量的酪胺会导致高血压危象。一系列最初无法解释的高血压危象确实发生了,有些甚至导致了中风。这种 "奶酪反应 "的原因在 20 世纪 60 年代末被揭开,但人们对高血压反应的恐惧依然存在。此外,在精神病学最早的一项大型随机临床试验3 中,有 260 名抑郁症患者接受了治疗,其中电痉挛疗法和丙咪嗪似乎都有效,而苯乙肼和安慰剂则无效。事后看来,人们很可能会认为,苯乙肼的治疗时间(4 周)和剂量(每天最多 60 毫克)都不够,因此,苯乙肼没有充分发挥其疗效潜力。随后,MAOIs 被认为是不太有效且危险的抗抑郁药物。受这种观念的影响,医生们更加青睐三环类抗抑郁药(TCA)而非 MAOIs。随着新型抗抑郁药,尤其是选择性血清素再摄取抑制剂(SSRIs)的开发,MAOIs 的使用率进一步下降。人们担心 MAOIs 的安全性,包括可能导致血清素综合征的潜在危险的药物间相互作用,以及高血压危象的风险,这些都限制了 MAOIs 的使用。此外,任何制药公司都没有推广使用 MAOIs。在一些国家,MAOIs 的处方数量极低:在 1,600 万人口中约有 500 名患者接受了治疗。精神科住院医师从优秀的培训项目毕业时可能几乎不了解 MAOIs,不知道 MAOIs 治疗的具体适应症,也不知道如何避免这些药物的安全性问题。因此,Gimenez-Palomo 等人的全面系统综述2 强调了 MAOIs 在重度抑郁症治疗中的作用,是一项宝贵的贡献。作者认为 MAOIs 和其他抗抑郁药的抗抑郁疗效相似。然而,正如 Lee 和 Wei6 在给编辑的信中针对该系统综述所指出的,在几种亚型重度抑郁症中,MAOIs 的疗效优于其他抗抑郁药。纽约哥伦比亚大学对非典型抑郁症患者进行了六项系列研究。在非典型抑郁症患者中,苯乙肼的疗效被证明优于丙咪嗪和安慰剂。7 这六项研究包括 409 名患者,安慰剂的总体反应率为 26%,丙咪嗪为 44%,而苯乙肼为 72%。Heijnen 等人8 在一项系统综述中发现,在双相抑郁症患者中,氨甲环丙胺(40-60 毫克)的总体应答率为 74%,而对照组的应答率为 28%。他们的研究结果强调了 Thase 和 Sachs9 在上一篇综述中的观点:"在其他条件相同的情况下,MAOI 类药物氨酰环丙胺可被视为双相抑郁症的首选治疗药物。
{"title":"Monoamine oxidase inhibitors: Seriously underused in the treatment of major depression","authors":"Tom K. Birkenhager,&nbsp;Willemijn T. Heijnen","doi":"10.1111/acps.13753","DOIUrl":"10.1111/acps.13753","url":null,"abstract":"&lt;p&gt;Monoamine oxidase inhibitors (MAOIs) were the first licensed antidepressants, they were discovered serendipitously, during a trial of iproniazid in patients with tuberculosis in the 1950s. Iproniazid appeared to have a “psychic energizing effect,” which resulted in the improvement of depressive symptoms in some tuberculosis patients,&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; around that time, iproniazid was shown to inhibit the MAO enzyme. Iproniazid was approved as an antidepressant, and this led to the development of several other MAOIs. Brain neurotransmitter levels are inactivated by MAO-A (serotonin, norepinephrine, dopamine) and MAO-B (dopamine) isoenzymes. Inhibition of the MAO enzyme leads to an increasing synaptic availability of these monoamines. In addition, tranylcypromine is similar in chemical structure to amphetamine and shares its dopamine-releasing and stimulant-like effects. Tranylcypromine and phenelzine are the most frequently used non-selective MAOIs, which bind the MAO enzyme irreversibly, and deactivate it permanently. Moclobemide is a selective MAO-A inhibitor, and enters into a reversible binding to the enzyme. Tranylcypromine and Phenelzine were widely prescribed until the late 1960s. The use of MAOIs has declined dramatically, as stated in their network meta-analysis by Gimenez-Palomo et al.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; The historical perspective is important in understanding this decline.&lt;/p&gt;&lt;p&gt;In the 1960s it was not well understood that MAOIs inhibit the breakdown of tyramine, and that excessive tyramine intake when using an MAOI, can lead to a hypertensive crisis. A series of initially unexplained hypertensive crises actually occurred, some even resulting in stroke. The cause of this “cheese reaction” was uncovered in the late 1960s, but the fear for the hypertensive reaction remained. Furthermore, in one of the first large randomized clinical trials in psychiatry,&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; which included 260 depressed patients, both ECT and imipramine appeared to be effective, whereas phenelzine and placebo were not. In hindsight, one may well argue, that both the duration of treatment with phenelzine (4 weeks) and its dose (maximum 60 mg daily) were insufficient, therefore, phenelzine fell short of its full efficacy potential. Subsequently, MAOIs were regarded as not very effective and dangerous antidepressant drugs. This perception influenced physicians to strongly favor tricyclic antidepressants (TCAs) over MAOIs. Usage of MAOIs further declined, following the development of newer antidepressants, especially the selective serotonin reuptake inhibitors (SSRIs). Concerns about the safety profile of MAOIs, including potentially dangerous drug–drug interactions, which could result in serotonin syndrome, and the risk of a hypertensive crisis restricted their use. Furthermore, the use of MAOIs was not promoted by any pharmaceutical company.&lt;/p&gt;&lt;p&gt;In several countries the number of prescriptions of MAOIs is extremely low: about 500 patie","PeriodicalId":108,"journal":{"name":"Acta Psychiatrica Scandinavica","volume":"150 6","pages":"497-499"},"PeriodicalIF":5.3,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/acps.13753","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142124284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mirtazapine in pregnancy and lactation: A systematic review of adverse outcomes 妊娠期和哺乳期的米氮平:不良后果的系统回顾。
IF 5.3 2区 医学 Q1 PSYCHIATRY Pub Date : 2024-08-31 DOI: 10.1111/acps.13749
Anne Ostenfeld, Sofie Lyngholm, Sarah Emilie Christensen, Tonny Studsgaard Petersen, Jon Trærup Andersen, Hanne Brix Westergaard, Lars Henning Pedersen, Ellen Christine Leth Løkkegaard

Introduction

Peripartum depression is common and treatment with mirtazapine may be indicated. However, evidence on its safety in pregnancy and lactation is fragmented.

The objective of this systematic review was to evaluate the literature on the safety of mirtazapine in pregnancy and lactation.

Methods

PubMed, Embase, Medline, PsycInfo, and clinicaltrials.gov were searched for ‘antidepressants’ or ‘mirtazapine’ in combination with ‘pregnancy’, ‘lactation’ or ‘offspring’.

No restrictions on type of study were applied and selection was performed by two independent reviewers using Covidence. Two reviewers extracted data and performed risk of bias assessment and evidence synthesis was performed for each outcome individually.

The protocol was registered at PROSPERO (registration number CRD42021275127).

Results

The initial search yielded 15,380 articles after removal of duplicates. After screening based on title and abstract, 431 articles remained for full text review. Of these, 41 studies were included (15 cohort studies, one case–control study, 11 case series, and 14 case reports). In most studies, the outcomes in mirtazapine-exposed pregnancies were comparable to controls. However, results on congenital malformations and spontaneous abortion were conflicting. Neonatal adaptation syndrome was reported after mirtazapine exposure in late pregnancy. Data on mirtazapine exposure during lactation were scarce.

Conclusions

We identified no substantial evidence indicating that mirtazapine exposure is associated with adverse outcomes in pregnancy or in offspring, other than neonatal adaptation syndrome. However, overall quality of evidence was low, and results on congenital malformations and spontaneous abortions were conflicting. Data on mirtazapine exposure through breastfeeding were limited and did not allow for conclusions.

简介围产期抑郁症很常见,可能需要使用米氮平进行治疗。然而,有关其在妊娠期和哺乳期安全性的证据并不完整。本系统综述旨在评估有关米氮平在妊娠期和哺乳期安全性的文献:方法:在 PubMed、Embase、Medline、PsycInfo 和 clinicaltrials.gov 中搜索 "抗抑郁药 "或 "米氮平",并结合 "妊娠"、"哺乳 "或 "后代"。研究类型不受限制,由两名独立审稿人使用 Covidence 进行筛选。两名审稿人提取数据并进行偏倚风险评估,对每项结果分别进行证据综合。研究方案已在 PROSPERO 注册(注册号为 CRD42021275127):在去除重复文章后,初步检索共获得 15,380 篇文章。根据标题和摘要进行筛选后,剩下 431 篇文章进行全文检讨。其中,41 项研究被纳入其中(15 项队列研究、1 项病例对照研究、11 项病例系列研究和 14 项病例报告)。在大多数研究中,暴露于米氮平的孕妇的结果与对照组相当。然而,关于先天性畸形和自然流产的结果却相互矛盾。有报告称,在妊娠晚期接触米氮平后会出现新生儿适应综合征。有关哺乳期接触米氮平的数据很少:除新生儿适应综合征外,我们没有发现任何实质性证据表明暴露于米氮平与妊娠期或后代的不良结局有关。然而,证据的总体质量较低,有关先天性畸形和自然流产的结果相互矛盾。通过母乳喂养接触米氮平的数据有限,无法得出结论。
{"title":"Mirtazapine in pregnancy and lactation: A systematic review of adverse outcomes","authors":"Anne Ostenfeld,&nbsp;Sofie Lyngholm,&nbsp;Sarah Emilie Christensen,&nbsp;Tonny Studsgaard Petersen,&nbsp;Jon Trærup Andersen,&nbsp;Hanne Brix Westergaard,&nbsp;Lars Henning Pedersen,&nbsp;Ellen Christine Leth Løkkegaard","doi":"10.1111/acps.13749","DOIUrl":"10.1111/acps.13749","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Peripartum depression is common and treatment with mirtazapine may be indicated. However, evidence on its safety in pregnancy and lactation is fragmented.</p>\u0000 \u0000 <p>The objective of this systematic review was to evaluate the literature on the safety of mirtazapine in pregnancy and lactation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>PubMed, Embase, Medline, PsycInfo, and clinicaltrials.gov were searched for ‘antidepressants’ or ‘mirtazapine’ in combination with ‘pregnancy’, ‘lactation’ or ‘offspring’.</p>\u0000 \u0000 <p>No restrictions on type of study were applied and selection was performed by two independent reviewers using Covidence. Two reviewers extracted data and performed risk of bias assessment and evidence synthesis was performed for each outcome individually.</p>\u0000 \u0000 <p>The protocol was registered at PROSPERO (registration number CRD42021275127).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The initial search yielded 15,380 articles after removal of duplicates. After screening based on title and abstract, 431 articles remained for full text review. Of these, 41 studies were included (15 cohort studies, one case–control study, 11 case series, and 14 case reports). In most studies, the outcomes in mirtazapine-exposed pregnancies were comparable to controls. However, results on congenital malformations and spontaneous abortion were conflicting. Neonatal adaptation syndrome was reported after mirtazapine exposure in late pregnancy. Data on mirtazapine exposure during lactation were scarce.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>We identified no substantial evidence indicating that mirtazapine exposure is associated with adverse outcomes in pregnancy or in offspring, other than neonatal adaptation syndrome. However, overall quality of evidence was low, and results on congenital malformations and spontaneous abortions were conflicting. Data on mirtazapine exposure through breastfeeding were limited and did not allow for conclusions.</p>\u0000 </section>\u0000 </div>","PeriodicalId":108,"journal":{"name":"Acta Psychiatrica Scandinavica","volume":"151 1","pages":"6-32"},"PeriodicalIF":5.3,"publicationDate":"2024-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/acps.13749","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142102337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Psychosis metabolic risk calculator (PsyMetRiC) in early psychosis: External validation study in Finland 早期精神病代谢风险计算器(PsyMetRiC):芬兰外部验证研究。
IF 5.3 2区 医学 Q1 PSYCHIATRY Pub Date : 2024-08-29 DOI: 10.1111/acps.13752
Jaakko Keinänen, Saana Eskelinen, Tiina From, Heikki Laurikainen, Jarmo Hietala, Graham K. Murray, Jaana Suvisaari, Benjamin I. Perry

Introduction

Accurate detection of cardiometabolic risk in early psychosis is crucial to reducing somatic morbidity and mortality in people with psychotic disorders. We conducted an external validation of the psychosis metabolic risk calculator (PsyMetRiC), a cardiometabolic risk prediction tool developed in the UK and tailored for young people with psychosis. We compared the predictive accuracy and clinical usefulness of PsyMetRiC and a general population-based risk prediction tool for type 2 diabetes, the Finnish Diabetes Risk Score (FINDRISC).

Methods

We included first-episode psychosis and ultra-high-risk for psychosis patients without metabolic syndrome aged 18–35 years from the Helsinki Early Psychosis and Turku Early Psychosis Study cohorts. We tested two versions of PsyMetRiC: the full model including age, sex, ethnicity, body-mass index, smoking status, prescription of metabolically-active antipsychotic medication, high-density lipoprotein, and triglyceride concentrations, and the partial-model excluding biochemical predictors, and the simplified FINDRISC including BMI, sex, systolic blood pressure, and fasting glucose. Discrimination, calibration, and decision curve analyses were used to assess the predictive performance and clinical usefulness of both PsyMetRiC and FINDRISC. We performed a site-specific re-calibration of PsyMetRiC (PsyMetRiC-Fi).

Results

The study sample consisted of 278 individuals (all White European ethnicity, 58.6% male, mean age 24.8 years, 37.8% smoking, mean BMI 23.5). Discrimination was marginally better in the PsyMetRiC full model (C = 0.72, 95% CI, 0.59–0.82) compared with partial model (C = 0.70, 95% CI 0.59–0.80) or FINDRISC (C = 0.63, 95% CI 0.54–0.71). Calibration plots displayed evidence of minor miscalibration for PsyMetRiC, which corrected following recalibration. Miscalibration was more pronounced for FINDRISC. Decision curve analysis showed that PsyMetRiC offers likely clinical usefulness in improving cardiometabolic risk management in early psychosis compared with giving everyone or no one an intervention.

Conclusion

PsyMetRiC has utility in predicting cardiometabolic risk in Finnish patients with early psychosis. It has better discriminatory accuracy and offers more accurate risk prediction compared to other available strategies.

导言:准确检测早期精神病患者的心脏代谢风险对于降低精神病患者的躯体发病率和死亡率至关重要。我们对精神病代谢风险计算器(PsyMetRiC)进行了外部验证,该计算器是英国开发的一种心脏代谢风险预测工具,专为患有精神病的年轻人量身定制。我们比较了 PsyMetRiC 和基于普通人群的 2 型糖尿病风险预测工具芬兰糖尿病风险评分(FINDRISC)的预测准确性和临床实用性:我们的研究对象包括赫尔辛基早期精神病研究队列和图尔库早期精神病研究队列中年龄在18-35岁之间、无代谢综合征的首发精神病患者和超高危精神病患者。我们测试了两个版本的 PsyMetRiC:包括年龄、性别、种族、体重指数、吸烟状况、代谢活性抗精神病药物处方、高密度脂蛋白和甘油三酯浓度在内的完整模型和排除生化预测因子的部分模型,以及包括体重指数、性别、收缩压和空腹血糖在内的简化 FINDRISC。我们使用辨别、校准和决策曲线分析来评估 PsyMetRiC 和 FINDRISC 的预测性能和临床实用性。我们对 PsyMetRiC(PsyMetRiC-Fi)进行了特定地点的重新校准:研究样本包括 278 人(均为欧洲白人,58.6% 为男性,平均年龄 24.8 岁,37.8% 吸烟,平均体重指数 23.5)。与部分模型(C = 0.70,95% CI 0.59-0.80)或 FINDRISC(C = 0.63,95% CI 0.54-0.71)相比,PsyMetRiC 完全模型(C = 0.72,95% CI,0.59-0.82)的识别率略高。校准图显示 PsyMetRiC 存在轻微的校准误差,在重新校准后得到纠正。FINDRISC 的误校正更为明显。决策曲线分析表明,与对所有人进行干预或不进行干预相比,PsyMetRiC 在改善早期精神病患者的心脏代谢风险管理方面可能具有临床实用性:结论:PsyMetRiC可用于预测芬兰早期精神病患者的心脏代谢风险。结论:PsyMetRiC可用于预测芬兰早期精神病患者的心脏代谢风险,与其他现有策略相比,它具有更好的鉴别准确性,并能提供更准确的风险预测。
{"title":"Psychosis metabolic risk calculator (PsyMetRiC) in early psychosis: External validation study in Finland","authors":"Jaakko Keinänen,&nbsp;Saana Eskelinen,&nbsp;Tiina From,&nbsp;Heikki Laurikainen,&nbsp;Jarmo Hietala,&nbsp;Graham K. Murray,&nbsp;Jaana Suvisaari,&nbsp;Benjamin I. Perry","doi":"10.1111/acps.13752","DOIUrl":"10.1111/acps.13752","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Accurate detection of cardiometabolic risk in early psychosis is crucial to reducing somatic morbidity and mortality in people with psychotic disorders. We conducted an external validation of the psychosis metabolic risk calculator (PsyMetRiC), a cardiometabolic risk prediction tool developed in the UK and tailored for young people with psychosis. We compared the predictive accuracy and clinical usefulness of PsyMetRiC and a general population-based risk prediction tool for type 2 diabetes, the Finnish Diabetes Risk Score (FINDRISC).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We included first-episode psychosis and ultra-high-risk for psychosis patients without metabolic syndrome aged 18–35 years from the Helsinki Early Psychosis and Turku Early Psychosis Study cohorts. We tested two versions of PsyMetRiC: the full model including age, sex, ethnicity, body-mass index, smoking status, prescription of metabolically-active antipsychotic medication, high-density lipoprotein, and triglyceride concentrations, and the partial-model excluding biochemical predictors, and the simplified FINDRISC including BMI, sex, systolic blood pressure, and fasting glucose. Discrimination, calibration, and decision curve analyses were used to assess the predictive performance and clinical usefulness of both PsyMetRiC and FINDRISC. We performed a site-specific re-calibration of PsyMetRiC (PsyMetRiC-Fi).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The study sample consisted of 278 individuals (all White European ethnicity, 58.6% male, mean age 24.8 years, 37.8% smoking, mean BMI 23.5). Discrimination was marginally better in the PsyMetRiC full model (<i>C</i> = 0.72, 95% CI, 0.59–0.82) compared with partial model (<i>C</i> = 0.70, 95% CI 0.59–0.80) or FINDRISC (<i>C</i> = 0.63, 95% CI 0.54–0.71). Calibration plots displayed evidence of minor miscalibration for PsyMetRiC, which corrected following recalibration. Miscalibration was more pronounced for FINDRISC. Decision curve analysis showed that PsyMetRiC offers likely clinical usefulness in improving cardiometabolic risk management in early psychosis compared with giving everyone or no one an intervention.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>PsyMetRiC has utility in predicting cardiometabolic risk in Finnish patients with early psychosis. It has better discriminatory accuracy and offers more accurate risk prediction compared to other available strategies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":108,"journal":{"name":"Acta Psychiatrica Scandinavica","volume":"151 1","pages":"56-68"},"PeriodicalIF":5.3,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/acps.13752","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142102338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Digital phenotypes of real-time suicidal ideation: Correlates and consequences 实时自杀意念的数字表型:相关因素和后果。
IF 5.3 2区 医学 Q1 PSYCHIATRY Pub Date : 2024-08-26 DOI: 10.1111/acps.13750
L. M. M. Kivelä, A. J. W. van der Does, R. Gilissen, Niki Antypa

Introduction

Suicidal ideation variability refers to within-day fluctuations in suicidal ideation, and has recently been proposed as an indicator of suicide risk. However, not much is known yet about its correlates and clinical relevance.

Methods

We examined characteristics of real-time suicidal ideation using Ecological Momentary Assessment in 82 individuals with current active suicidal ideation. Data were collected four times daily over 21 days. Latent profile analysis was used to identify subtypes of suicidal ideation. We further examined sociodemographic and clinical correlates of the profiles, and their association with the occurrence of suicide attempts during a 1-year follow-up.

Results

We identified three “digital” phenotypes of suicidal ideation that differed on the frequency, intensity and variability of ideation. The profiles were: high frequency, high intensity, moderate variability (Phenotype 1), moderate/high frequency, moderate intensity, high variability (Phenotype 2), and moderate frequency, low intensity, low variability (Phenotype 3). Phenotypes 1 and 2 were associated with a worse clinical profile at baseline (higher suicidal ideation and depressive symptom severity), and increased odds of suicide attempt during follow-up, compared to Phenotype 3. Phenotype 1 was further characterized by repeated suicidal behavior.

Conclusions

Two phenotypes of real-time suicidal ideation were identified that appear to confer a higher risk of suicidal behavior in the near future (12 months). These phenotypes were characterized by higher variability of suicidal ideation—and also higher intensity and frequency of ideation. Considering the small sample size, the clinical usefulness of the profiles remains to be demonstrated.

简介自杀意念变异性是指自杀意念在一天之内的波动,最近被提出作为自杀风险的一个指标。然而,人们对其相关性和临床意义还知之甚少:方法:我们使用生态学瞬间评估对 82 名当前有主动自杀意念的人的实时自杀意念特征进行了研究。数据收集为期 21 天,每天四次。我们使用潜伏特征分析来确定自杀意念的亚型。我们进一步研究了这些特征的社会人口学和临床相关性,以及它们与一年随访期间自杀未遂发生率的关联:结果:我们发现了自杀意念的三种 "数字 "表型,它们在自杀意念的频率、强度和可变性方面各不相同。它们分别是:高频率、高强度、中等变异性(表型 1),中等/高频率、中等强度、高变异性(表型 2),以及中等频率、低强度、低变异性(表型 3)。与表型 3 相比,表型 1 和表型 2 的基线临床特征更差(自杀意念和抑郁症状严重程度更高),随访期间自杀未遂的几率更高。表型 1 的另一个特点是反复出现自杀行为:结论:研究发现了两种实时自杀意念表型,它们似乎会在不久的将来(12 个月)带来更高的自杀行为风险。这些表型的特点是自杀意念的变异性更高,意念的强度和频率也更高。考虑到样本量较小,这些特征的临床实用性还有待证实。
{"title":"Digital phenotypes of real-time suicidal ideation: Correlates and consequences","authors":"L. M. M. Kivelä,&nbsp;A. J. W. van der Does,&nbsp;R. Gilissen,&nbsp;Niki Antypa","doi":"10.1111/acps.13750","DOIUrl":"10.1111/acps.13750","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Suicidal ideation variability refers to within-day fluctuations in suicidal ideation, and has recently been proposed as an indicator of suicide risk. However, not much is known yet about its correlates and clinical relevance.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We examined characteristics of real-time suicidal ideation using Ecological Momentary Assessment in 82 individuals with current active suicidal ideation. Data were collected four times daily over 21 days. Latent profile analysis was used to identify subtypes of suicidal ideation. We further examined sociodemographic and clinical correlates of the profiles, and their association with the occurrence of suicide attempts during a 1-year follow-up.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We identified three “digital” phenotypes of suicidal ideation that differed on the frequency, intensity and variability of ideation. The profiles were: high frequency, high intensity, moderate variability (Phenotype 1), moderate/high frequency, moderate intensity, high variability (Phenotype 2), and moderate frequency, low intensity, low variability (Phenotype 3). Phenotypes 1 and 2 were associated with a worse clinical profile at baseline (higher suicidal ideation and depressive symptom severity), and increased odds of suicide attempt during follow-up, compared to Phenotype 3. Phenotype 1 was further characterized by repeated suicidal behavior.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Two phenotypes of real-time suicidal ideation were identified that appear to confer a higher risk of suicidal behavior in the near future (12 months). These phenotypes were characterized by higher variability of suicidal ideation—and also higher intensity and frequency of ideation. Considering the small sample size, the clinical usefulness of the profiles remains to be demonstrated.</p>\u0000 </section>\u0000 </div>","PeriodicalId":108,"journal":{"name":"Acta Psychiatrica Scandinavica","volume":"151 3","pages":"375-387"},"PeriodicalIF":5.3,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/acps.13750","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142071480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Age-stratified risk of suicide in patients with schizophrenia 精神分裂症患者自杀的年龄分层风险。
IF 5.3 2区 医学 Q1 PSYCHIATRY Pub Date : 2024-08-14 DOI: 10.1111/acps.13747
Yueh-Pin Lin, Wen-Yin Chen, Chun-Hung Pan, Sheng-Shiang Su, Shang-Ying Tsai, Chiao-Chicy Chen, Chian-Jue Kuo

Objectives

Schizophrenia is associated with an increased risk of suicide. Few studies have investigated the risk of suicide across different ages, likely due to limitations around sample size.

Methods

From the National Health Insurance Research Database in Taiwan, this study identified 195,787 patients with schizophrenia from January 1, 2000, to December 31, 2019. During the study period, 3848 patients died from suicide. We calculated the standardized mortality ratio (SMR) for suicide stratified by age. In this age-stratified, nested case–control study, risk set sampling was used to match each case with 4 living controls by age, sex, and the year of the first diagnosis with schizophrenia. Conditional logistic regression was used for estimating age-stratified risk profiles.

Results

The SMR was the highest in the <25 years age group (52.8) and inversely correlated with age. Unemployment was associated with an increased risk of suicide in the 25 to 34, 35 to 44, 45 to 54, and 55 to 64 years age groups. Depressive and sleep disorders before suicide were more common among suicide cases with schizophrenia than among controls across all age groups. Drug-induced and alcohol-induced mental disorders were significantly associated with suicide but were observed only in the age group younger than 54. Heart disease, pneumonia, and moderate or severe renal disease were risk factors for suicide in the age groups less than 65.

Conclusions

The risk factors for suicide differ by age. This study's findings can be used to optimize health-care interventions for preventing suicide in patients with schizophrenia.

目的:精神分裂症与自杀风险增加有关。可能由于样本量的限制,很少有研究调查不同年龄段的自杀风险:本研究从台湾的 "国民健康保险研究数据库 "中筛选出 195,787 名精神分裂症患者,时间跨度为 2000 年 1 月 1 日至 2019 年 12 月 31 日。在研究期间,有 3848 名患者死于自杀。我们计算了按年龄分层的自杀标准化死亡率(SMR)。在这项按年龄分层的嵌套病例对照研究中,我们采用了风险集抽样法,按照年龄、性别和首次确诊精神分裂症的年份,将每个病例与 4 个在世的对照组进行匹配。条件逻辑回归用于估算年龄分层风险概况:结论:SMR 在《结论》中最高:自杀的风险因素因年龄而异。这项研究的结果可用于优化医疗干预措施,预防精神分裂症患者自杀。
{"title":"Age-stratified risk of suicide in patients with schizophrenia","authors":"Yueh-Pin Lin,&nbsp;Wen-Yin Chen,&nbsp;Chun-Hung Pan,&nbsp;Sheng-Shiang Su,&nbsp;Shang-Ying Tsai,&nbsp;Chiao-Chicy Chen,&nbsp;Chian-Jue Kuo","doi":"10.1111/acps.13747","DOIUrl":"10.1111/acps.13747","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Schizophrenia is associated with an increased risk of suicide. Few studies have investigated the risk of suicide across different ages, likely due to limitations around sample size.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>From the National Health Insurance Research Database in Taiwan, this study identified 195,787 patients with schizophrenia from January 1, 2000, to December 31, 2019. During the study period, 3848 patients died from suicide. We calculated the standardized mortality ratio (SMR) for suicide stratified by age. In this age-stratified, nested case–control study, risk set sampling was used to match each case with 4 living controls by age, sex, and the year of the first diagnosis with schizophrenia. Conditional logistic regression was used for estimating age-stratified risk profiles.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The SMR was the highest in the &lt;25 years age group (52.8) and inversely correlated with age. Unemployment was associated with an increased risk of suicide in the 25 to 34, 35 to 44, 45 to 54, and 55 to 64 years age groups. Depressive and sleep disorders before suicide were more common among suicide cases with schizophrenia than among controls across all age groups. Drug-induced and alcohol-induced mental disorders were significantly associated with suicide but were observed only in the age group younger than 54. Heart disease, pneumonia, and moderate or severe renal disease were risk factors for suicide in the age groups less than 65.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The risk factors for suicide differ by age. This study's findings can be used to optimize health-care interventions for preventing suicide in patients with schizophrenia.</p>\u0000 </section>\u0000 </div>","PeriodicalId":108,"journal":{"name":"Acta Psychiatrica Scandinavica","volume":"150 6","pages":"530-542"},"PeriodicalIF":5.3,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141981266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Progress in perinatal mental health research 围产期心理健康研究的进展。
IF 5.3 2区 医学 Q1 PSYCHIATRY Pub Date : 2024-08-13 DOI: 10.1111/acps.13746
Kristina M. Deligiannidis, Jennifer L. Payne
<p>Perinatal psychiatric and substance use disorders are common, yet suboptimal treatment is frequent.<span><sup>1</sup></span> Underdiagnosis and undertreatment of perinatal psychiatric and substance use disorders is associated with poor maternal functioning, increased risk for adverse obstetrical and neonatal outcomes, and abnormal child socioemotional regulation including effects on cognitive and executive function and stress responsivity.<span><sup>2, 3</sup></span> This special issue highlights the importance of the growing subspecialty of perinatal psychiatry with its rich cross-disciplinary approach bridging diverse specialties including obstetrics, neonatology, developmental pediatrics, child and adult psychiatry, psychology, psychiatric epidemiology, neuroscience, and more.</p><p>In this issue, several studies focus on risks associated with the development of perinatal psychiatric disorders or their relationship with a variety of maternal and infant outcomes. Johannsen et al. reported that the baseline risk of developing a mild to severe postpartum psychiatric episode was 6.9%, while for young mothers with a personal and family history of psychiatric disorders, the absolute risk rose to 21.6%, and rose further to 29.2% when information on high genetic liability to depression was added.<span><sup>4</sup></span> While this risk calculation may not include all potential risk factors for an individual patient, these well-established personal risk factors when combined make it possible to identify a vulnerable group of women at significant risk for a postpartum psychiatric episode. Related, Schoretsanitis et al. reported that postpartum hemorrhage, which affects up to one-tenth of women giving birth, is a risk factor for the development of postpartum depression, a risk which was further increased in women with a history of depression or anxiety.<span><sup>5</sup></span></p><p>Huizink et al. examined the normative courses of pregnancy-related anxiety in a large birth cohort.<span><sup>6</sup></span> They identified two distinct trajectories of pregnancy-related anxiety, a low-symptom group (88.6%) with lower and slightly increasing levels of pregnancy-related anxiety, and a moderately high symptoms group (11.4%) who reported higher and slightly decreasing levels of anxiety. The presence of moderately high symptoms was correlated with several general risk factors for mental health disorders including a lower income, use of alcohol or smoking early in pregnancy, more early life adversities, younger age, primiparity, and single parenthood, among others. The authors suggest that women with high levels of pregnancy anxiety throughout pregnancy may need more clinical attention, as their symptoms may point to the presence of other mental health disorder risk factors, which together may negatively affect fetal and infant development and behavior.</p><p>A second group of studies focus on perinatal psychiatric disorder treatments. Research into the trea
14 这种独特的方法使婴儿的抑郁症状和焦虑症状都有了统计学意义上的显著减少,并改善了婴儿的负性情绪。Rommel 等人15 主导的研究探讨了母亲的重度抑郁症遗传责任是否可以解释孕期使用抗抑郁药与较低胎龄和出生体重之间的部分关联。他们证实,孕期服用抗抑郁药与胎龄和出生体重的小幅降低有关。然而,他们发现抑郁症的遗传责任与风险并非线性相关,因此可能仍然存在残余混杂因素,潜在的混杂因素包括怀孕期间的抑郁症状。鉴于妊娠可能是意外的,而且大多数妊娠可能在器官形成过程中才会被发现,因此处方医生应该对所有有可能怀孕的患者进行孕前咨询。在这些共同决策对话中,除了潜在的治疗益处外,还应讨论和记录未经治疗的精神疾病对母婴二人的风险,以及治疗的已知风险(和目前未知的潜在风险)。异丙孕酮在围产期抑郁症的病理生理学方面一直受到积极研究16-18 ,异丙孕酮及其类似物唑拉诺酮已在美国开发用于治疗产后抑郁症19-21。Hare 等人22 报告了围产期抑郁症严重程度与异丙孕酮浓度之间的单向时间关联,以及抑郁症严重程度和异丙孕酮浓度与与情绪调节和认知控制有关的脑区产后结构变化之间的特定关联。这项研究强调了围产期抑郁严重程度、异孕烷醇酮浓度和产后灰质体积之间错综复杂的相互作用,为了解围产期抑郁的神经机制及其对针对性干预的潜在影响提供了宝贵的见解。另一项研究探讨了围产期抑郁与脑源性神经营养因子(BDNF)之间的关系,BDNF 参与神经元生长、神经元分化和突触可塑性,可在外周血中测定,被认为可反映脑组织中的 BDNF 水平。荟萃分析表明,产前抑郁症患者和产后抑郁症患者的脑源性神经营养因子水平均显著下降。首先,了解在这一关键时期的最佳治疗策略,从而优化父母和儿童的治疗效果,对于减少悲剧的发生和将围产期精神疾病的影响降至最低至关重要。其次,确定风险因素和生物标志物,尤其是确定围产期精神疾病高危人群的风险因素和生物标志物,最终将有助于临床治疗的预防性而非被动性。最后,围产期精神疾病的发病时间是可以预测的,因此可以在发病前后对各种生物过程进行测量,从而对潜在的病理生理学进行研究。找出产后抑郁症等疾病的生物学过程,很可能会加深对重度抑郁症的理解,进而改善治疗方法和总体疗效。本特刊表明,围产期心理健康研究正在取得进展。我们期待看到这些重要发现的临床影响。KMD还担任Sage Therapeutics、Biogen、Brii Biosciences、Gerbera Therapeutics、Neuroscience Software和Reunion Neuroscience的顾问。KMD 曾担任由 Sage Therapeutics、Nesos Corporation、Gerbera Therapeutics、Woebot Health 和 Premier Healthcare 授予费恩斯坦医学研究所(Feinstein Institutes for Medical Research)的合同研究的主要研究员。JLP获得了美国国立卫生研究院、杨森制药公司(Janssen Pharmaceuticals)和Myriad Genetics公司的研究支持。佩恩博士拥有两项专利:"产后抑郁症的表观遗传生物标志物 "和 "经前多愁善感症和 SSRI 反应的表观遗传生物标志物"。佩恩博士拥有 Dionysus Health 创始人股票期权。佩恩博士
{"title":"Progress in perinatal mental health research","authors":"Kristina M. Deligiannidis,&nbsp;Jennifer L. Payne","doi":"10.1111/acps.13746","DOIUrl":"10.1111/acps.13746","url":null,"abstract":"&lt;p&gt;Perinatal psychiatric and substance use disorders are common, yet suboptimal treatment is frequent.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; Underdiagnosis and undertreatment of perinatal psychiatric and substance use disorders is associated with poor maternal functioning, increased risk for adverse obstetrical and neonatal outcomes, and abnormal child socioemotional regulation including effects on cognitive and executive function and stress responsivity.&lt;span&gt;&lt;sup&gt;2, 3&lt;/sup&gt;&lt;/span&gt; This special issue highlights the importance of the growing subspecialty of perinatal psychiatry with its rich cross-disciplinary approach bridging diverse specialties including obstetrics, neonatology, developmental pediatrics, child and adult psychiatry, psychology, psychiatric epidemiology, neuroscience, and more.&lt;/p&gt;&lt;p&gt;In this issue, several studies focus on risks associated with the development of perinatal psychiatric disorders or their relationship with a variety of maternal and infant outcomes. Johannsen et al. reported that the baseline risk of developing a mild to severe postpartum psychiatric episode was 6.9%, while for young mothers with a personal and family history of psychiatric disorders, the absolute risk rose to 21.6%, and rose further to 29.2% when information on high genetic liability to depression was added.&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt; While this risk calculation may not include all potential risk factors for an individual patient, these well-established personal risk factors when combined make it possible to identify a vulnerable group of women at significant risk for a postpartum psychiatric episode. Related, Schoretsanitis et al. reported that postpartum hemorrhage, which affects up to one-tenth of women giving birth, is a risk factor for the development of postpartum depression, a risk which was further increased in women with a history of depression or anxiety.&lt;span&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Huizink et al. examined the normative courses of pregnancy-related anxiety in a large birth cohort.&lt;span&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/span&gt; They identified two distinct trajectories of pregnancy-related anxiety, a low-symptom group (88.6%) with lower and slightly increasing levels of pregnancy-related anxiety, and a moderately high symptoms group (11.4%) who reported higher and slightly decreasing levels of anxiety. The presence of moderately high symptoms was correlated with several general risk factors for mental health disorders including a lower income, use of alcohol or smoking early in pregnancy, more early life adversities, younger age, primiparity, and single parenthood, among others. The authors suggest that women with high levels of pregnancy anxiety throughout pregnancy may need more clinical attention, as their symptoms may point to the presence of other mental health disorder risk factors, which together may negatively affect fetal and infant development and behavior.&lt;/p&gt;&lt;p&gt;A second group of studies focus on perinatal psychiatric disorder treatments. Research into the trea","PeriodicalId":108,"journal":{"name":"Acta Psychiatrica Scandinavica","volume":"150 5","pages":"249-252"},"PeriodicalIF":5.3,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11444868/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141974530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnostic value of structural, functional and effective connectivity in bipolar disorder 双相情感障碍的结构连接、功能连接和有效连接的诊断价值。
IF 5.3 2区 医学 Q1 PSYCHIATRY Pub Date : 2024-08-13 DOI: 10.1111/acps.13742
Teodora M. Gencheva, Bozhidar V. Valkov, Sevdalina S. Kandilarova, Michael H. J. Maes, Drozdstoy S. Stoyanov

Introduction

The aim of this systematic review is to assess the functional magnetic resonance imaging (fMRI) studies of bipolar disorder (BD) patients that characterize differences in terms of structural, functional, and effective connectivity between the patients with BD, patients with other psychiatric disorders and healthy controls as possible biomarkers for diagnosing the disorder using neuroimaging.

Methods

Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), guidelines a systematic search for recent (since 2015) original studies on connectivity in bipolar disorder was conducted in PUBMED and SCOPUS.

Results

A total of 60 studies were included in this systematic review: 20 of the structural connectivity, 33 of the functional connectivity, and only 7 of the studies focused on effective connectivity complied with the inclusion and exclusion criteria.

Discussion

Despite the great heterogeneity in the findings, there are several trends that emerge. In structural connectivity studies, the main abnormalities in bipolar disorder patients were in the frontal gyrus, anterior, as well as posterior cingulate cortex and differences in emotion and reward-related networks. Cerebellum (vermis) to cerebrum functional connectivity was found to be the most common finding in BD. Moreover, prefrontal cortex and amygdala connectivity as part of the rich-club hubs were often reported to be disrupted. The most common findings based on effective connectivity were alterations in salience network, default mode network and executive control network.

Although more studies with larger sample sizes are needed to ascertain altered brain connectivity as diagnostic biomarker, there is a perspective that the method could be used as a single marker of diagnosis in the future, and the process of adoption could be accelerated by using approaches such as semiunsupervised machine learning.

导言:本系统性综述旨在评估双相情感障碍(BD)患者的功能磁共振成像(fMRI)研究,这些研究描述了双相情感障碍患者、其他精神疾病患者和健康对照组之间在结构、功能和有效连接性方面的差异,并将其作为利用神经影像学诊断双相情感障碍的可能生物标志物:根据《系统综述和荟萃分析首选报告项目》(PRISMA)指南,在 PUBMED 和 SCOPUS 上对近期(2015 年以来)有关双相情感障碍连通性的原创研究进行了系统检索:本系统性综述共纳入了 60 项研究:20项结构连通性研究、33项功能连通性研究,只有7项关注有效连通性的研究符合纳入和排除标准:讨论:尽管研究结果存在很大的异质性,但还是出现了一些趋势。在结构连接研究中,双相情感障碍患者的主要异常部位是额回、前扣带回和后扣带回皮层,情绪和奖赏相关网络也存在差异。小脑(蚓部)到大脑的功能连接是双相情感障碍最常见的发现。此外,前额叶皮层和杏仁核作为富俱乐部枢纽的一部分,其连接也经常被报告为中断。基于有效连接的最常见发现是显著性网络、默认模式网络和执行控制网络的改变。虽然需要更多样本量更大的研究来确定大脑连通性的改变作为诊断生物标志物,但有一种观点认为,这种方法在未来可用作诊断的单一标志物,而采用半无监督机器学习等方法可加快采用的进程。
{"title":"Diagnostic value of structural, functional and effective connectivity in bipolar disorder","authors":"Teodora M. Gencheva,&nbsp;Bozhidar V. Valkov,&nbsp;Sevdalina S. Kandilarova,&nbsp;Michael H. J. Maes,&nbsp;Drozdstoy S. Stoyanov","doi":"10.1111/acps.13742","DOIUrl":"10.1111/acps.13742","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>The aim of this systematic review is to assess the functional magnetic resonance imaging (fMRI) studies of bipolar disorder (BD) patients that characterize differences in terms of structural, functional, and effective connectivity between the patients with BD, patients with other psychiatric disorders and healthy controls as possible biomarkers for diagnosing the disorder using neuroimaging.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), guidelines a systematic search for recent (since 2015) original studies on connectivity in bipolar disorder was conducted in PUBMED and SCOPUS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 60 studies were included in this systematic review: 20 of the structural connectivity, 33 of the functional connectivity, and only 7 of the studies focused on effective connectivity complied with the inclusion and exclusion criteria.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Discussion</h3>\u0000 \u0000 <p>Despite the great heterogeneity in the findings, there are several trends that emerge. In structural connectivity studies, the main abnormalities in bipolar disorder patients were in the frontal gyrus, anterior, as well as posterior cingulate cortex and differences in emotion and reward-related networks. Cerebellum (vermis) to cerebrum functional connectivity was found to be the most common finding in BD. Moreover, prefrontal cortex and amygdala connectivity as part of the rich-club hubs were often reported to be disrupted. The most common findings based on effective connectivity were alterations in salience network, default mode network and executive control network.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <p>Although more studies with larger sample sizes are needed to ascertain altered brain connectivity as diagnostic biomarker, there is a perspective that the method could be used as a single marker of diagnosis in the future, and the process of adoption could be accelerated by using approaches such as semiunsupervised machine learning.</p>\u0000 </section>\u0000 </div>","PeriodicalId":108,"journal":{"name":"Acta Psychiatrica Scandinavica","volume":"151 3","pages":"192-209"},"PeriodicalIF":5.3,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/acps.13742","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141974529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Acta Psychiatrica Scandinavica
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1